Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.
Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.
复制标题
DOI:
10.1126/sciimmunol.abj2901
复制
发表时间:
2021-10-15
影响因子:
24.8
通讯作者:
Alter G
中科院分区:
文献类型:
--
作者:
Kaplonek P;Wang C;Bartsch Y;Fischinger S;Gorman MJ;Bowman K;Kang J;Dayal D;Martin P;Nowak RP;Villani AC;Hsieh CL;Charland NC;Gonye ALK;Gushterova I;Khanna HK;LaSalle TJ;Lavin-Parsons KM;Lilley BM;Lodenstein CL;Manakongtreecheep K;Margolin JD;McKaig BN;Rojas-Lopez M;Russo BC;Sharma N;Tantivit J;Thomas MF;Sade-Feldman M;Feldman J;Julg B;Nilles EJ;Musk ER;Menon AS;Fischer ES;McLellan JS;Schmidt A;Goldberg MB;Filbin MR;Hacohen N;Lauffenburger DA;Alter G
Preexisting cross-coronavirus immunity influences the early development of SARS-CoV-2 humoral immunity after COVID-19. There are many correlates of protection to SARS-CoV-2 infection, but it is unclear how previously established immune responses to common seasonal coronaviruses might correlate to COVID-19 protection. Here, Kaplonek and Wang et al. looked at the early antibody responses to SARS-CoV-2 and the common cold β-coronavirus OC43 in the blood of COVID-19 patients with asymptomatic, moderate, severe, or deadly disease. They found that initial antibody responses to SARS-CoV-2 correlated with antibodies against OC43 in patients who survived COVID-19 and experienced milder disease. Thus, this work suggests that immunity to common seasonal coronaviruses may help to protect against SARS-CoV-2 infection. The introduction of vaccines has inspired hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against SARS-CoV-2, thus we profiled the earliest humoral signatures in a large cohort of acutely ill (survivors and nonsurvivors) and mild or asymptomatic individuals with COVID-19. Although a SARS-CoV-2–specific immune response evolved rapidly in survivors of COVID-19, nonsurvivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibodies. Given the conservation of S2 across β-coronaviruses, we found that the early development of SARS-CoV-2–specific immunity occurred in tandem with preexisting common β-coronavirus OC43 humoral immunity in survivors, which was also selectively expanded in individuals that develop a paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.
登录
查看更多内容
影响因子:
16.6
作者:
Bartsch YC;Fischinger S;Siddiqui SM;Chen Z;Yu J;Gebre M;Atyeo C;Gorman MJ;Zhu AL;Kang J;Burke JS;Slein M;Gluck MJ;Beger S;Hu Y;Rhee J;Petersen E;Mormann B;Aubin MS;Hasdianda MA;Jambaulikar G;Boyer EW;Sabeti PC;Barouch DH;Julg BD;Musk ER;Menon AS;Lauffenburger DA;Nilles EJ;Alter G
通讯作者:
Alter G
DOI:
10.1016/j.xcrm.2021.100290
发表时间:
2021-06-15
期刊:
Cell reports. Medicine
影响因子:
--
作者:
Anand SP;Prévost J;Nayrac M;Beaudoin-Bussières G;Benlarbi M;Gasser R;Brassard N;Laumaea A;Gong SY;Bourassa C;Brunet-Ratnasingham E;Medjahed H;Gendron-Lepage G;Goyette G;Gokool L;Morrisseau C;Bégin P;Martel-Laferrière V;Tremblay C;Richard J;Bazin R;Duerr R;Kaufmann DE;Finzi A
通讯作者:
Finzi A
DOI:
10.1016/j.clim.2020.108651
发表时间:
2021-03
期刊:
Clinical immunology (Orlando, Fla.)
影响因子:
--
作者:
Gasmi A;Peana M;Pivina L;Srinath S;Gasmi Benahmed A;Semenova Y;Menzel A;Dadar M;Bjørklund G
通讯作者:
Bjørklund G
影响因子:
7.3
作者:
Fierz, Walter;Walz, Brigitte
通讯作者:
Walz, Brigitte
影响因子:
24.8
作者:
Isho B;Abe KT;Zuo M;Jamal AJ;Rathod B;Wang JH;Li Z;Chao G;Rojas OL;Bang YM;Pu A;Christie-Holmes N;Gervais C;Ceccarelli D;Samavarchi-Tehrani P;Guvenc F;Budylowski P;Li A;Paterson A;Yue FY;Marin LM;Caldwell L;Wrana JL;Colwill K;Sicheri F;Mubareka S;Gray-Owen SD;Drews SJ;Siqueira WL;Barrios-Rodiles M;Ostrowski M;Rini JM;Durocher Y;McGeer AJ;Gommerman JL;Gingras AC
通讯作者:
Gingras AC